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Pergolide-induced lung disease in patients with
Parkinson’s disease
J. A.KASTELIK, I. AZIZ,M. A.GREENSTONE, R.THOMPSONAND A.H.MORICE
Academic Department of Medicine,University of Hull,Castle Hill Hospital,Castle Road,Cottingham,
East Yorkshire,U.K.INTRODUCTION
Synthetic dopamine agonists including pergolide have ac-
quired wide usage in the management of Parkinson’s dis-
ease (1). These agents have been associated with a
number of side e¡ects including nausea, orthostatic hy-
potension, confusion, paranoia and visual hallucinations
(1,2). In addition, they can cause unusual but severe com-
plications such as pericarditis, retroperitoneal and pleur-
al ¢brosis (3). However, they have not been known to
produce interstitial lung disease.We report on two pa-
tients who developed reversible interstitial lung injury
whilst taking pergolide.
CASE1
A 52-year-old woman presented in 1999, with an 18-
month history of gradually worsening non-productive
cough. She had developed Parkinson’s disease in 1993
and pergolide was introduced 2 years later as her symp-
toms were not controlled with levodopa. At the time of
presentation, her therapy consisted of pergolide 4.5mg
daily (approximate cumulative dose of 5.9 g) and a combi-
nation of carbidopa and levodopa.
Examination showed mild Parkinsonism, aortic and
mitral regurgitation, and no abnormal respiratory signs.
Blood count, biochemical pro¢le and autoantibody
screen were unremarkable. The chest radiograph was
normal but the high-resolution computed tomograph
(HRCT) scan showed di¡use ground-glass shadowing
suggestive of acute alveolitis (Fig. 1). The bronchoscopy
and limited transbronchial biopsies were normal. Lung
function tests showed a restrictive defect with an FEV1
of1.83 l (predicted 2.44 l), FVC of 2.18 l (predicted 2.87 l),
and a residual volume of1.15 l (predicted1.71l). However,Received 9 October 2001, accepted in revised form 8 January 2002.
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drug-induced alveolitis due to pergolidewasmade.
On stopping pergolide, the patient’s cough decreased
and this was con¢rmed objectively by measuring reduc-
tion in cough sensitivityusing serial inhalation cough chal-
lenges with citric acid (Fig. 2). Following an initial
improvement, the patient’s symptoms recurred with an
associated increase in cough sensitivity on repeated
cough challenge testing. Immunosuppression with pre-
dnisolone 1mg/kg and cyclophosphamide 100mg daily
was started.This change in therapyresultedin resolution
of symptoms within 3 months (Fig. 2). Immunosuppres-
sive therapy was stopped 3 months later. Repeat HRCT
scan showed resolution without ¢brosis and lung func-
tion revealed FEV1, FVC and transfer factor, all within
thenormal range.Thepatientremains stable on a combi-
nation of entacapone, carbidopa and levodopa.
CASE 2
A64-year-oldmanknown tohave Parkinson’s disease for
15-years was admittedwith a1-week history of lethargy,
breathlessness and dry cough. Pergolide had been intro-
duced 4 years previously (a maintenance dose of 1.5mg
daily, an approximate cumulative dose of 2.1g) in addition
to amantadine and a combination of benserazide hydro-
chloride and levodopa.
On examination, the heart sounds were soft with mi-
tral regurgitation. There were bilateral inspiratory
crackles with basal dullness. The ESR was 89mm/h, but
the autoimmune screen was normal. The chest radio-
graph showedanenlargedheartwithbilateral interstitial
shadowing and pleural e¡usions [Fig. 3 (a)]. The pleural
aspiratewas sterile on culture, showedmixed in£amma-
tory cells with predominance of lymphocytes and had a
protein content of 27g/l (serum protein of 59 g/l), and
the LDHof 467m/l.The echocardiogramrevealed normal
left ventricular function and thepresence of a pericardial
e¡usion but no evidence of right ventricular collapse.
The HRCT scan of the thorax showed bilateral upper
CASEREPORT 549lobe airspace shadowing with areas of con£uence and
more di¡use patchy ground-glass opaci¢cation [Fig. 3
(b)]. The patient was unable to perform lung function
measurements.
A diagnosis of pergolide-induced pneumonitis with
pleural and pericardial e¡usions was made. Pergolide
was stopped and the patient’s symptoms improvedwith-
in 2 weeks.The chest radiograph showed improvement
of pulmonary shadowing and diminution of the pleural
and pericardial e¡usions. Two months later, he was
asymptomatic and the chest radiograph was normal.
The patient remains stable on amantadine and a combi-
nation of benserazide hydrochloride and levodopa.FIG. 1. HRCTscanofthethoraxinthe ¢rstpatient showingdif-
fuse ground-glass shadowing suggestive of acute alveolitis.
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FIG 2. Serial cough challenge testing with citric acid (1 and 1000
showing initialresponse to glucocorticosteroids followedbyrelapseDISCUSSION
Pergolide is a synthetic dopamine agonist and, like ergot
fromwhich it is derived, has been associated with atypi-
cal sclerotic disorders such as retroperitoneal (4,5),
pleural, and pericardial ¢brosis (3).We report a hitherto
undescribed complication of pergolide therapymanifest-
ing as two di¡erent forms of interstitial lungdisease.Our
¢rst patient presented with chronic cough, and ground-
glass shadowing on the CTscan, suggesting an alveolitis.
The in£ammatory process continued despite the cessa-
tion of pergolide and only abated following the introduc-
tion of corticosteroids and cyclophosphamide. In
contrast, the second patient presentedwith an acute ill-
ness and a rapid recovery after stopping pergolide.
While therewas a strong cause/e¡ect relationship be-
tween the drug and the lung disorders in both described
cases, wewere unable to obtain con¢rmatory histologi-
cal evidence of the underlying pathological process in
case1and itwas not attempted in case 2.The patchy dis-
tribution of the in£ammatory reaction as seen on CT
scanswas probably the reason for the lackof histological
con¢rmation from transbronchial sampling in case 1.
However, the presence of ground-glass opaci¢cation on
CT in both cases is strongly suggestive of an underlying
alveolitis. In case 2, the CTalso showed changes sugges-
tive of bronchiolitis obliterans organising pneumonia
(BOOP), an increasingly recognised condition where ¢-
bromyxoid connective tissue is deposited within small
airways and air spaces (6).
Heightened cough re£ex has been described in pa-
tients with interstitial lung diseases (7,8), and therefore
the assessment of cough response has been suggested
as a non-invasive method of monitoring e¡ects of treat-
ment in this condition (7). The clinical application of
cough challenge was apparent in our ¢rst patient. The4 5
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and the e¡ectof immunosuppressive therapy.
FIG 3. Chest radiograph (a) and the HRCTof the thorax (b) in
the secondpatient at presentation.
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£ammatory process and the decrease of cough sensitiv-
ity as a result of cessation of pergolide preceded the
radiographic improvement. The underlying mechanism
for the altered regulation of cough re£ex observed in
case1 and other patients with interstitial lung disorders
(7,8) is unknown but it may re£ect sensitisation of the
cough receptor by the in£ammatorymediators.
Whilst a rechallenge to pergolidewas notundertaken,
the presentation of both the described cases would ful¢l
criteria for attribution of a de¢nite drug-related adverse
event, as proposed by Karch and Lasagna (9). A similarlong latency period between the commencement of per-
golide and the development of symptomswas previously
described (3). The adverse reactions corresponded to
the known pharmacological pro¢le of pergolide and
other synthetic dopamine agonists. The symptoms and
radiological abnormalities in both of our patients re-
mitted on cessation of pergolide.However, as the aetiol-
ogy of interstitial lung injury due to pergolide is not
known, we could hypothesise that the underlying me-
chanism is an idiosyncratic immune response (3). Cer-
tainly, drug-induced lupus is an unlikely explanation in
our patients because the antinuclear factor remained
negative. More importantly, cardiac failure or infection
would not explain the symptoms of our second patient
as the left ventricular function was normal and pleural
aspiratewas sterile.
In conclusion, clinicians shouldbe aware thatpergolide
may cause interstitial lung disease which can manifest
after a long period of latency.Therefore, we recommend
that patients who receive this type of therapy should be
advised to report all new respiratory symptoms to their
physicians and consideration given to HRCT imaging if
symptoms fail to resolve rapidly.
These adverse eventswere reported to theMedicines
Control Agency.
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